Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C13H10F3N5 and a molecular weight of approximately 293.25 g/mol. It belongs to the class of triazolopyrimidines and features both methyl and trifluoromethyl substituents on its aromatic rings. The compound is listed as an experimental molecule in drug databases but has no approved medical indications or known clinical development programs. Its mechanism of action and biological targets are not specified in available public resources. There are no records of FDA or EMA approval for this substance as a pharmaceutical agent[1][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine.